{'fraction_non_alphanumeric': 0.03161397670549085, 'fraction_numerical': 0.0, 'mean_word_length': 4.901960784313726, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Molecular and cellular aspects of cis-diamminedichloroplatinum (II) interactions with DNA].

Cis-DDP is an antitumor drug with activity against various human tumors. It is generally accepted that DNA is the cellular target of cis-DDP. The present paper describes the binding models of cis-DDP to DNA, structural distortion in DNA induced by covalent binding of cis-DDP and repair studies of Pt-DNA adducts in pro- and eukaryotic systems. We also discuss the possible mechanisms of acquired resistance of cancerous cells to cis-DDP and analogues, and potential clinical implication of this phenomenon.